Page 188 - Read Online

Gim et al. Hepatoma Res 2023;9:51 https://dx.doi.org/10.20517/2394-5079.2023.90 Page 17 of 20

14. Thein KZ, Biter AB, Banks KC, et al. Identification of KRASG12C mutations in circulating tumor DNA in patients with cancer. JCO
Precis Oncol 2022;6:e2100547. DOI PubMed PMC
15. Demols A, Rocq L, Charry M, et al. NTRK gene fusions in biliary tract cancers. JCO 2020;38:574. DOI
16. Parimi V, Tolba K, Danziger N, et al. Genomic landscape of 891 RET fusions detected across diverse solid tumor types. NPJ Precis
Oncol 2023;7:10. DOI PubMed PMC
17. Yu J, Zhang X, Huang Q, Tan S, Xiong X, Gou H. Rare DNA mismatch repair-related protein loss in patients with intrahepatic
cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma and their response to immunotherapy. Cancer Manag Res
2021;13:4283-90. DOI PubMed PMC
18. Silva VW, Askan G, Daniel TD, et al. Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency. Chin Clin
Oncol 2016;5:62. DOI
19. Shao C, Li G, Huang L, et al. Prevalence of high tumor mutational burden and association with survival in patients with less common
solid tumors. JAMA Netw Open 2020;3:e2025109. DOI PubMed PMC
20. Tian W, Zhang W, Wang Y, et al. Recent advances of IDH1 mutant inhibitor in cancer therapy. Front Pharmacol 2022;13:982424.
DOI PubMed PMC
21. NCCN clinical practice guidelines in oncology (NCCN Guidelines®) biliary tract cancers, version 2.2023. Available from: https://
www.nccn.org/professionals/physician_gls/pdf/btc.pdf [Last accessed on 25 Dec 2023].
22. FDA approves ivosidenib for advanced or metastatic cholangiocarcinoma. Available from: https://www.fda.gov/drugs/resources-
information-approved-drugs/fda-approves-ivosidenib-advanced-or-metastatic-cholangiocarcinoma [Last accessed on 25 Dec 2023].
23. Study of LY3410738 administered to patients with advanced solid tumors with IDH1 or IDH2 mutations. Available from: https://
classic.clinicaltrials.gov/ct2/show/NCT04521686 [Last accessed on 25 Dec 2023].
24. A study of HMPL-306 in advanced solid tumors with IDH mutations. Available from: https://classic.clinicaltrials.gov/ct2/show/
NCT04762602 [Last accessed on 25 Dec 2023].
25. A study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations. Available from: https://classic.
clinicaltrials.gov/ct2/show/NCT02381886 [Last accessed on 25 Dec 2023].
26. Gemcitabine and cisplatin with ivosidenib or pemigatinib for the treatment of unresectable or metastatic cholangiocarcinoma.
Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04088188 [Last accessed on 25 Dec 2023].
27. Borad M, Javle M, Shaib W, et al. 59P Efficacy of derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2
fusions, mutations or amplifications. Ann Oncol 2022;33:S567-8. DOI
28. Hollebecque A, Borad M, Goyal L, et al. LBA12 Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an
FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial. Ann Oncol
2022;33:S1381. DOI
29. Ohba A, Morizane C, Kawamoto Y, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing
unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial). JCO
2022;40:4006. DOI
30. Harding JJ, Fan J, Oh DY, et al; HERIZON-BTC-01 study group. Zanidatamab for HER2-amplified, unresectable, locally advanced
or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol 2023;24:772-82.
DOI PubMed
31. Harding JJ, Lowery MA, Shih AH, et al. Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase
inhibition. Cancer Discov 2018;8:1540-7. DOI PubMed PMC
32. Cleary JM, Rouaisnel B, Daina A, et al. Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired
resistance to ivosidenib in cholangiocarcinoma. NPJ Precis Oncol 2022;6:61. DOI PubMed PMC
33. Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol 2015;4:215-66. DOI PubMed
PMC
34. Acevedo VD, Ittmann M, Spencer DM. Paths of FGFR-driven tumorigenesis. Cell Cycle 2009;8:580-8. DOI PubMed PMC
35. Silverman IM, Murugesan K, Lihou CF, et al. Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable
alterations in advanced cholangiocarcinoma. JCO 2019;37:4080. DOI
36. Javle MM, Murugesan K, Shroff RT, et al. Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA),
tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH). JCO 2019;37:4087. DOI
37. Meric-Bernstam F, Bahleda R, Hierro C, et al. Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors
harboring FGF/FGFR aberrations: a phase I dose-expansion study. Cancer Discov 2022;12:402-15. DOI PubMed PMC
38. Goyal L, Kongpetch S, Crolley VE, Bridgewater J. Targeting FGFR inhibition in cholangiocarcinoma. Cancer Treat Rev
2021;95:102170. DOI PubMed
39. Farha N, Dima D, Ullah F, Kamath S. Precision oncology targets in biliary tract cancer. Cancers 2023;15:2105. DOI PubMed PMC
40. FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR rearrangement or fusion. Available from:
2
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pemigatinib-cholangiocarcinoma-
fgfr2-rearrangement-or-fusion [Last accessed on 25 Dec 2023].
41. Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic
cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 2020;21:671-84. DOI PubMed PMC
42. Vogel A, Sahai V, Hollebecque A, et al. O-2 Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: